alexa Treatment Of Metabolic Acidosis In Chronic Kidney Disease Yields Better Weight Control With Fruits And Vegetables Than With Currently Recommended Sodium-based Alkali Therapy
ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

10th International Conference and Exhibition on Obesity & Weight Management
December 08-10, 2016 Dallas, USA

Donald E Wesson, Nimrit Goraya, Jan Simoni and Jessica Pruszynski
Baylor Scott and White Health, USA
Texas A&M HSC College of Medicine, USA
Texas Tech University Health Sciences Center, USA
Diabetes Health and Wellness Institute, USA
ScientificTracks Abstracts: J Obes Weight Loss Ther
DOI: 10.4172/2165-7904.C1.042
Background: Current guidelines recommend sodium-based alkali therapy for metabolic acidosis in chronic kidney disease (CKD) but recent data support that base-producing fruits and vegetables (F+V) also improve metabolic acidosis in CKD. Because CKD increases cardiovascular risk, weight reduction in overweight CKD patients appears desirable given its cardiovascular and other benefits. A diet high in F+V might promote weight reduction as well as improve metabolic acidosis in CKD. Methods: We randomized 108 subjects with CKD stage 3 estimated glomerular filtration rate (30-59 ml/min/1.73 m2), metabolic acidosis with plasma total CO2 (PTCO2) >22 but <24 mM, and baseline BMI >25 as follows: F+V (n=36) added to reduce dietary potential renal acid load (PRAL) 50%, oral NaHCO3 (HCO3, n=36) to reduce PRAL 50%, or no alkali (Usual Care, n=36). All received standard kidney protection measures and were followed for 5 years. Results: Baseline PTCO2 (23.0±0.6, 23.1±0.6, and 23.0±0.5, p=0.62) and BMI (28.8±2.1, 28.3±2.0, and 28.2±2.1, p=0.45) were not different among F+V, HCO3, and Usual Care, respectively. Five-year PTCO2 was higher in HCO3 (23.9±0.4 mM) and F+V (23.8±0.4 mM) than Usual Care (21.9±0.4 mM, p <0.01 vs. HCO3 and F+V). By contrast, five-year BMI was lower (p<0.03) in F+V (26.6±1.7) than both HCO3 (28.4±1.9) and Usual Care (27.8±1.7). Conclusions: Treating CKD patients with either NaHCO3 or F+V improved metabolic acidosis similarly but BMI was lowest with F+V. Better weight control with F+V than NaHCO3, the latter being the currently recommended treatment option, supports F+V as the preferred treatment strategy for metabolic acidosis in overweight CKD patients.

Donald E Wesson, MD, FACP is currently Professor of Medicine and the Vice Dean of Texas A&M University College of Medicine in Temple, Texas. Prior to this position, he was the S C Arnett Professor of Medicine and Chairman of the Department of Internal Medicine and Physiology at Texas Tech University Health Sciences Center and had been Associate Professor of Medicine at the Baylor College of Medicine where he was Assistant Chief of the Nephrology Section at the Houston VA Hospital. He received his undergraduate degree from the Massachusetts Institute of Technology. He earned his Medical Degree from Washington University School of Medicine and completed his Residency and Internship at Baylor College of Medicine. He is the recipient of multiple teaching awards at Baylor and Texas Tech.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version